National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Bosentan (Tracleer®) is indicated for the treatment pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO Functional Class (FC) III and WHO FC II.  It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

Rapid Review

Commenced Completed Outcome
27/06/2014 04/07/2014 Full Pharmacoeconomic Evaluation Not Recommended